Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Solid Biosciences (SLDB) Net Income (2017 - 2024)

Solid Biosciences' Net Income history spans 8 years, with the latest figure at -$38.0 million for Q4 2024.

  • For Q4 2024, Net Income fell 84.64% year-over-year to -$38.0 million; the TTM value through Dec 2024 reached -$120.6 million, down 24.19%, while the annual FY2024 figure was -$120.6 million, 24.19% down from the prior year.
  • Net Income for Q4 2024 was -$38.0 million at Solid Biosciences, down from -$32.9 million in the prior quarter.
  • Across five years, Net Income topped out at -$16.9 million in Q1 2021 and bottomed at -$38.0 million in Q4 2024.
  • The 5-year median for Net Income is -$22.8 million (2020), against an average of -$24.1 million.
  • The largest annual shift saw Net Income skyrocketed 37.62% in 2023 before it tumbled 84.64% in 2024.
  • A 5-year view of Net Income shows it stood at -$21.4 million in 2020, then rose by 12.69% to -$18.7 million in 2021, then plummeted by 77.1% to -$33.0 million in 2022, then surged by 37.62% to -$20.6 million in 2023, then crashed by 84.64% to -$38.0 million in 2024.
  • Per Business Quant, the three most recent readings for SLDB's Net Income are -$38.0 million (Q4 2024), -$32.9 million (Q3 2024), and -$25.3 million (Q2 2024).